ligufalimab

Ligufalimab is a next-generation humanized immunoglobulin G4 (IgG4) monoclonal antibody that targets the leukocyte surface antigen CD47. By blocking the interaction between CD47 and SIRPα, ligufalimab disrupts an antiphagocytic signal that cancer cells use to evade immune clearance, thereby enhancing macrophage-mediated phagocytosis of tumor cells. Unlike earlier anti-CD47 antibodies, ligufalimab does not induce hemagglutination or anemia, addressing key safety concerns in this drug class. It is being developed primarily for hematologic malignancies such as myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumors including squamous cell cancer, cholangiocarcinoma, colorectal cancer, gastric cancer, liver cancer, esophageal cancer, triple negative breast cancer, lymphoma and oropharyngeal cancer. Ligufalimab is under clinical investigation both as monotherapy and in combination with other agents such as azacitidine[1][3][4][6][7].

Other names

Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer